NEW YORK, NY--(Marketwired - October 11, 2013) - Tonix Pharmaceuticals Holding Corp. (TNXP), a development stage specialty pharmaceutical company, will participate in the upcoming Women's Healthcare Innovation and Leadership Showcase, on Tuesday, October 15, 2013 in Bridgewater, NJ. The event, hosted by the Healthcare Businesswomen's Association, in partnership with Sanofi, Quintiles and HealthyWomen.org, will take place from 6:00-9:30 PM (ET) on the Sanofi campus.
"Approximately 80 to 90 percent of those patients diagnosed with fibromyalgia are women and we believe this forum may help bring greater recognition to fibromyalgia and to Tonix's clinical progress," said Seth Lederman, M.D., CEO and President of Tonix. "This forum provides us an important opportunity to discuss our clinical pipeline and technology alongside some of our larger pharmaceutical company peers, including Novartis, Purdue Pharma, and Sanofi, which we believe will encourage a greater understanding of both Tonix and the treatment areas we are pursuing as well as expand our perspective on this target population."
Tonix 's is one of the curated exhibits selected for its impact in advancing women's health. The company will showcase TNX-102 SL, its lead clinical candidate for the treatment of fibromyalgia and post-traumatic stress disorder. Tonix recently announced the initiation of its BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) clinical trial, which is the first of two anticipated pivotal trials for TNX-102 SL 2.8 mg tablets in patients with fibromyalgia.
In April of this year, the United States Food and Drug Administration (FDA) selected fibromyalgia as a disease upon which to focus for the next two fiscal years. The Administration will be conducting a meeting this December on fibromyalgia under Patient-Focused Drug Development, an initiative that involves obtaining a better understanding of patients' perspectives on the severity of the disease and the available therapies for the condition. These activities demonstrate an increased awareness of fibromyalgia and its impact among the U.S. population.
About the HBA
The Healthcare Businesswomen's Association (HBA) is in its fourth decade as a global not-for-profit organization dedicated to furthering the advancement of women in healthcare worldwide. With 15 chapters throughout the US and in Europe, the HBA is headquartered in New Jersey with offices in Philadelphia and Research Triangle Park. The HBA provides: networking forums to build relationships; knowledge-sharing and access to thought leaders to broaden perspective; educational programs to develop leadership skills and cutting edge industry knowledge and recognition of outstanding women and companies to promote visibility of their achievements. The HBA has over 6,200 individual members and 100 Corporate Partners. It is widely recognized as the catalyst for leadership development of women in healthcare worldwide. For more information, please visit www.HBAnet.org.
About Tonix Pharmaceuticals Holding Corp.
Tonix is developing innovative prescription medications for challenging disorders of the central nervous system. The Company seeks to address conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among patients and physicians. Tonix's lead pharmaceutical candidate, TNX-102 SL, targets central pain. Fibromyalgia is a central pain syndrome, and central pain is a component of post-traumatic stress disorder. Tonix applies its core technology toward the treatment of people suffering from central pain disorders by targeting their inability to obtain restorative sleep. To learn more, please visit www.tonixpharma.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on TONIX's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. TONIX does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on March 11, 2013 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.